Could a daily pill replace eye injections for diabetic retinopathy?
NCT ID NCT04692688
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This study tested an oral medication called APX3330 in 103 adults with diabetic retinopathy, a leading cause of vision loss. The pill aims to reduce inflammation and low-oxygen damage in the eye. Researchers measured whether it could improve the severity of the disease over 24 weeks compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Site 1
Rapid City, South Dakota, 57701, United States
-
Clinical Site 10
Fort Worth, Texas, 76104, United States
-
Clinical Site 11
Palm Desert, California, 92260, United States
-
Clinical Site 12
Albuquerque, New Mexico, 87113, United States
-
Clinical Site 13
Southlake, Texas, 76092, United States
-
Clinical Site 14
Hagerstown, Maryland, 21740, United States
-
Clinical Site 15
Shirley, New York, 11967, United States
-
Clinical Site 16
Bellaire, Texas, 77030, United States
-
Clinical Site 17
Grand Blanc, Michigan, 48439, United States
-
Clinical Site 18
Austin, Texas, 78705, United States
-
Clinical Site 19
Miami, Florida, 33143, United States
-
Clinical Site 2
Sacramento, California, 95825, United States
-
Clinical Site 20
Charlotte, North Carolina, 28210, United States
-
Clinical Site 21
Ogden, Utah, 84010, United States
-
Clinical Site 22
Springfield, Massachusetts, 01107, United States
-
Clinical Site 23
San Antonio, Texas, 78624, United States
-
Clinical Site 24
Walnut Creek, California, 94598, United States
-
Clinical Site 3
San Antonio, Texas, 78240, United States
-
Clinical Site 4
McAllen, Texas, 78550, United States
-
Clinical Site 5
Beverly Hills, California, 91607, United States
-
Clinical Site 6
Carmel, Indiana, 46290, United States
-
Clinical Site 7
Winter Haven, Florida, 33880, United States
-
Clinical Site 8
Bakersfield, California, 93309, United States
-
Clinical Site 9
Phoenix, Arizona, 85014, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APX3330 (an oral tablet that targets inflammation and low oxygen in the eye)
What this could lead to
If it works, this could offer a pill-based option to slow vision loss from diabetic retinopathy, reducing the need for eye injections.
What could go wrong
This is an early Phase 2 trial with only 103 participants. The drug may not improve vision enough, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.